ELTX
Elicio Therapeutics, Inc.8.15
-0.37-4.34%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
140.66MP/E (TTM)
-Basic EPS (TTM)
-3.11Dividend Yield
0%Recent Filings
8-K
AMPLIFY-7P DFS delayed to 1H26
10-Q
Q3 FY2025 results
Elicio trimmed operating expenses to $8.0M in Q3 ended September 30, 2025, down 22% y/y from $10.3M, driving a $10.1M net loss versus $18.8M last year; the gap widened by fair value changes in warrant liabilities. R&D fell 30% y/y to $5.0M as Phase 2 ELI-002 7P patients progressed. Cash sits at $20.6M with $9.7M net long-term debt (June 2025 Promissory Note to GKCC at prime+5%, due 2028); operating cash burn hit $30.2M YTD. Converted $20M senior note to equity in March. Cash funds to Q2 2026. Warrants swing earnings.
8-K
ELI-002 7P hits 99% response
Elicio Therapeutics disclosed Phase 2 AMPLIFY-7P immunogenicity data on September 17, 2025, showing ELI-002 7P triggered robust mKRAS-specific T cell responses in 99% of 90 evaluable patients, with 145.3x average and 44.3x median fold increases over baseline—outpacing Phase 1 results. Responses hit 85% for CD4/CD8 cells and 67.4% across all seven antigens. Data mirrors Phase 1 levels linked to clinical activity. Final DFS readout awaits Q4 2025.
8-K
ELI-002 OS hits 28.94 months
Elicio Therapeutics published Phase 1 AMPLIFY-201 follow-up data for ELI-002 in Nature Medicine, showing median OS jumping to 28.94 months at 19.7-month follow-up in MRD-positive adjuvant patients. Strong mKRAS T-cell responses cut death risk 77% and relapse risk 88% in responders. ELI-002 proved safe. Phase 2 AMPLIFY-7P final DFS data due Q4 2025.
8-K
IDMC clears ELI-002 trial
Elicio Therapeutics reported Q2 net loss of $10.6M, with R&D expenses dropping to $7.0M from $8.2M due to less manufacturing. IDMC greenlit the ELI-002 7P Phase 2 pancreatic cancer trial to final DFS analysis in Q4 2025, confirming safety. $10M non-dilutive financing boosted cash to $22.1M, funding ops into Q1 2026. Cash extends past key data readout.
BNTX
BioNTech SE
92.23-1.52
ELVN
Enliven Therapeutics, Inc.
16.91-0.26
IOBT
IO Biotech, Inc.
0.69-0.02
LIXT
Lixte Biotechnology Holdings, I
4.10+0.11
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
MRKR
Marker Therapeutics, Inc.
1.27-0.12
NBTX
Nanobiotix S.A.
22.32+0.18
NWBO
Northwest Biotherapeutics, Inc.
0.25+0.01
PHIO
Phio Pharmaceuticals Corp.
1.08-0.01
XLO
Xilio Therapeutics, Inc.
0.65+0.00